Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35247086)

  • 1. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
    Bagegni NA; Park H; Kraft K; O-Toole M; Gao F; Waqar SN; Ratner L; Morgensztern D; Devarakonda S; Amin M; Baggstrom MQ; Liang C; Selvaggi G; Wang-Gillam A
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):487-497. PubMed ID: 35247086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
    Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
    Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
    EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
    Beckermann KE; Bestvina CM; El Osta B; Sanborn RE; Borghaei H; Lammers PE; Selvaggi G; Whisenant JG; Heimann-Nichols E; Berry L; Hsu CY; Shyr Y; Horn L; Wakelee H
    JTO Clin Res Rep; 2024 Feb; 5(2):100619. PubMed ID: 38328473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
    Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
    Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
    Hong DS; Postow M; Chmielowski B; Sullivan R; Patnaik A; Cohen EEW; Shapiro G; Steuer C; Gutierrez M; Yeckes-Rodin H; Ilaria R; O'Connell B; Peng J; Peng G; Zizlsperger N; Tolcher A; Wolchok JD
    Clin Cancer Res; 2023 Jun; 29(12):2210-2219. PubMed ID: 37000164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.
    Song Y; Wang J; Ren X; Jin J; Mao L; Liang C; Ding L; Yang L
    Chin J Cancer Res; 2021 Feb; 33(1):103-114. PubMed ID: 33707933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
    Bendell JC; Patel MR; Moore KN; Chua CC; Arkenau HT; Dukart G; Harrow K; Liang C
    Oncologist; 2019 Apr; 24(4):455-e121. PubMed ID: 30478190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the
    Kim C; Liu SV; Subramaniam DS; Torres T; Loda M; Esposito G; Giaccone G
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
    Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
    JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
    Gong J; Cao J; Zhang Q; Xu N; Zhao Y; Xing B; Miao Z; Wu Y; Pan H; Gao Q; Li X; Liu B; Li W; Pei Z; Xia H; Qi Q; Dai H; Shi Q; Yang J; Li J; Shen L
    Cancer Immunol Immunother; 2022 Aug; 71(8):1897-1908. PubMed ID: 34984540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.